CDT Equity Files Two New Patent Applications to Expand Tapinarof IP
CDT Equity announced the filing of two new patent applications that further expand the company's intellectual property portfolio surrounding tapinarof, a drug currently approved for the treatment of psoriasis and atopic dermatitis. The first patent covers a combination therapy pairing tapinarof with a class of drugs clinically proven in psoriasis and atopic dermatitis, while the second patent relates to novel cocrystal forms of tapinarof with these agents. CDT stated it intends to pursue out-licensing opportunities with pharmaceutical companies.
